About

The Client

Novartis reimagines medicine to improve and extend people’s lives using innovative science and technology to address some of society’s most challenging healthcare issues. They discover and develop breakthrough treatments and find new ways to deliver them to as many people as possible.

About

The Project

Indacaterol is a novel, ultra-long-acting, rapid onset β(2)-adrenoceptor agonist developed for Novartis for the once-daily management of asthma and chronic obstructive pulmonary disease. It was approved by the European Medicines Agency (EMA) under the trade name Onbrez on November 30, 2009.